Pipetting robot for academic research - 28/08/2024 goodBot GmbH: a third arm for researchers Repetitive tasks that researchers have to conduct in the lab tend to be tiring and often lead to errors. Precise pipetting is crucial for achieving reproducible results. Automation is underrepresented in research labs and existing pipetting robots are unsuitable for scientists. This is why Dr. Julius Wiener, Tobias Zundel and Oliver Brunner decided to found the company goodBot GmbH and develop a pipetting robot tailored to academic research.
Tablet-based diagnostics - 12/04/2023 TuCAN - innovative diagnostic procedure for neuropsychiatric disorders Neuropsychiatric disorders are often diagnosed late and have a negative impact on quality of life. Diagnosing the disease at an early stage is vital to be able to help those affected by offering them treatment adapted to their specific requirements. This is what the TuCAN project in Tübingen aims to achieve through the early and differential diagnosis of neuropsychiatric disorders.
Press release - 25/08/2026 Revier Therapeutics Launches with €6 Million Seed Financing to Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease Revier Therapeutics, today announced the closing of a EUR 6 million seed financing and the launch of its operations. The Company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases.
Press release - 13/05/2026 NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies NVision announced a $55 million Series B led by Abbott and unveiled PIQC, a new quantum computing platform built on its molecular quantum technology.
